Picture Berlin Partner Top News Robotics Network Berlin-Brandenburg 650x100px

Product › Details

topoisomerase inhibitor

	Next higher product group	cancer drug
	Status	1996-01-01 registration start
	Status	1997-01-01 sales existent

Record changed: 2024-07-14

Picture Berlin Partner Life Sciences Report 2024-2025 650x200px

More documents for cancer drug

[1] Callio Therapeutics. (3/3/25). "Press Release: Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept". Seattle, WA & Singapore....
[2] Siemens Healthineers AG. (12/10/24). "Press Release: Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging"....
[3] Ipsen S.A.. (12/3/24). "Press Release: Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-Class MAIT Cell Engager in Immuno-oncology". Paris....
[4] Alentis Therapeutics AG. (11/12/24). "Press Release: Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors". Basel....
[5] Innate Pharma S.A.. (10/14/24). "Press Release: Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board"....
[6] Alentis Therapeutics AG. (9/3/24). "Press Release: Alentis Appoints Jonathan Freve CFO". Basel....
[7] Catalym GmbH. (7/16/24). "Press Release: Catalym Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab". Munich....
[8] Ipsen S.A.. (7/11/24). "Press Release: Ipsen and Foreseen Biotechnology Announce Exclusive Global Licensing Agreement for Antibody-Drug Conjugate with First-in-Class Potential". Paris....
[9] Myricx Pharma Ltd.. (7/8/24). "Press Release: Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development". London....
[10] Tacalyx GmbH. (6/11/24). "Press Release: Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)